Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Otsuka to acquire Neurovance

by Ann M. Thayer
March 13, 2017 | A version of this story appeared in Volume 95, Issue 11

Otsuka Pharmaceutical will pay $100 million up front and up to $150 million in potential milestone payments to acquire Cambridge, Mass.-based Neurovance, a six-year-old company focused on attention-deficit/hyperactivity disorder. Its lead ADHD candidate is centanafadine, which has completed Phase II clinical trials. According to Neurovance, centanafadine is one of a new generation of triple reuptake inhibitors that modulate the activity of norepinephrine, dopamine, and serotonin. The acquisition will extend Otsuka’s efforts in the area of central nervous system therapy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.